Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients With Advanced/Metastatic Solid Tumors or Lymphomas.
Funda Meric-BernstamRandy F SweisF Stephen HodiWells A MessersmithRobert H I AndtbackaMatthew InghamNancy LewisXinhui ChenMarc PelletierXueying ChenJincheng WuSarah M McWhirterThomas MüllerNitya NairJason John LukePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
MIW815 was well tolerated in patients with advanced/metastatic cancers. Clinical activity of single-agent MIW815 was limited in this first-in-human study, however, evidence of systemic immune activation was seen.